Intrinsic Value of S&P & Nasdaq Contact Us

Baxter International Inc. BAX NYSE

NYSE • Healthcare • Medical - Instruments & Supplies • US • USD

SharesGrow Score
43/100
2/7 Pass
SharesGrow Intrinsic Value
$25.54
+45.2%
Analyst Price Target
$19.75
+12.3%

Baxter International Inc. (BAX) generated $584M in operating cash flow for quarter ending 2025-12-31. After capital expenditures of $140M, free cash flow was $444M.

Free cash flow margin was 14.9% of revenue. Cash conversion ratio was -0.56x, suggesting some earnings are non-cash.

The company returned $87M in dividends to shareholders during the quarter.

Criteria supported by this page:

  • HEALTH (33/100, Fail) — weak cash flow raises concerns about debt servicing
  • MOAT (49/100, Partial) — cash flow generation is present but not at levels indicating a wide moat
  • INCOME (10/100) — Cash conversion ratio was -0.56x suggests some earnings are non-cash items

Overall SharesGrow Score: 43/100 with 2/7 criteria passed.

SharesGrow 7-Criteria Score
43/100
SG Score
View full scorecard →
VALUE
78/100
Price-to-Earnings & upside
→ Valuation
~
FUTURE
40/100
Analyst consensus
→ Forecast
PAST
25/100
→ Income
HEALTH
33/100
Debt-to-Equity & liquidity
Proven by this page
~
MOAT
49/100
Proven by this page
GROWTH
63/100
→ Income
INCOME
10/100
→ Income
Baxter International Inc. Cash Flow History
Metric TTM Q4 FY2025 Q3 FY2025 Q2 FY2025 Q1 FY2025
Operating Cash Flow $845M$584M$237M$217M$-193M
Capital Expenditure $-522M$-140M$-111M$-149M$-122M
Free Cash Flow $323M$444M$126M$68M$-315M
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
Send us a message